Image source: Shutterstock

Highlights

  • PRTC’s FY24 revenue rose by 44.7% yoy, primarily driven by a milestone payment received from Bristol Myers Squibb.
  • The company recorded a profit of USD 27.78 million for the period.
  • PureTech advanced multiple internal R&D programs into the clinical development phase.

PureTech Health PLC (LSE: PRTC) listed on FTSE 250 index is a clinical-stage biotherapeutics company focused on developing innovative medicines that aim to transform the lives of patients suffering from severe diseases.

In the financial year 2024 (FY24), the company’s revenue increased by 44.7% yoy to USD 4.82 million, primarily driven by a USD 4.0 million milestone payment received from Bristol Myers Squibb. The company’s net cash position grew 12.5% yoy to USD 366.81 million, providing an operational runway to support pipeline development. Meanwhile, profit rose to USD 27.78 million, reversing the previous year’s loss, primarily driven by improved cost discipline, milestone income, and tax benefits.

Recent Business Update

PureTech received a USD 100 million milestone payment from Karuna following its acquisition by Bristol Myers Squibb, highlighting its ability to translate early innovation into tangible returns.
The company also advanced several internal R&D programs, including LYT-300 and LYT-310, into the clinical development phase.

Company Outlook

The company is strengthening sustainability and governance reporting to meet investor expectations and support long-term investment appeal. Following the monetization of its Karuna stake, PureTech redirected capital to its wholly owned pipeline, enhancing focus on assets with full rights and long-term value.

Top 10 Shareholders of PRTC

The top 10 shareholders of PRTC collectively hold approximately ~65.41% of the company’s shares. Invesco Asset Management Limited holds the largest stake at around ~17.07%, followed by Lansdowne Partners (UK) LLP with approximately ~9.10%.

Stock Information

The stock has witnessed a fall of ~4.08% in the past three months, whereas it has gained around 4.60% in the past month. The stock has a 52-week low and 52-week high of GBX 100.40 & GBX 238.50, respectively, and is currently below the average of the 52-week high-low with a closing price of GBX 136.2 as of 30 May 2025.

Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 30 May 2025. The reference data in this report has been partly sourced from EODHD/Others.

Technical Indicators Defined

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.